--- title: "Omeros Corporation to Announce First Quarter Financial Results on May 13, 2026 | OMER Stock News" type: "News" locale: "en" url: "https://longbridge.com/en/news/285988162.md" description: "Omeros Corporation (NASDAQ: OMER) will announce its first quarter financial results for 2026 on May 13, 2026, after market close. A conference call and webcast will follow at 4:30 p.m. ET to discuss the results and recent developments. Omeros is a biotechnology company focused on developing therapeutics for complement-mediated diseases and has FDA-approved products, including YARTEMLEA® for TA-TMA. The company is also advancing its pipeline, including OMS1029 and OMS527, with various partnerships and ongoing clinical trials." datetime: "2026-05-11T12:02:00.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/285988162.md) - [en](https://longbridge.com/en/news/285988162.md) - [zh-HK](https://longbridge.com/zh-HK/news/285988162.md) --- # Omeros Corporation to Announce First Quarter Financial Results on May 13, 2026 | OMER Stock News SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER) today announced that it will issue its financial results for the first quarter 2026 on Wednesday, May 13, 2026 after market close. Omeros management will host a conference call and webcast that same day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss recent developments and highlights as well as the Company’s financial results. **Conference Call Details and Webcast Link Instructions** To access the live webcast, please click here or visit the “Upcoming Events” section of the Investor Relations page of Omeros’ website. A replay of the call will be available for 90 days in the “Archived Events” section of the Investor Relations page of Omeros’ website. As Omeros continues to transition to a new earnings call platform (hosted by Q4 Inc.), please allow extra time to log in prior to the start of the call. **About Omeros Corporation** Omeros is an innovative biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for both large-market and orphan indications, with a focus on complement-mediated diseases, cancers, and addictive or compulsive disorders. Omeros’ lead complement inhibitor YARTEMLEA® (narsoplimab-wuug), which targets the lectin pathway’s effector enzyme MASP-2, is FDA-approved and commercially available in the U.S. for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA) in adult and pediatric patients aged two years and older. A marketing authorization application seeking approval of YARTEMLEA for TA-TMA is currently under review at the European Medicines Agency. OMS1029, Omeros’ long-acting MASP-2 inhibitor, has successfully completed Phase 1 clinical trials. Under a recently announced asset purchase and licensing agreement, Novo Nordisk acquired global rights to zaltenibart (formerly OMS906), an inhibitor of MASP-3, the alternative pathway’s key activator, which is in clinical development for PNH and other alternative pathway indications, along with associated intellectual property and related assets. Omeros’ pipeline also includes OMS527, a phosphodiesterase 7 inhibitor in clinical development for cocaine use disorder, which is fully funded by the National Institute on Drug Abuse, and a growing portfolio of novel recombinant antibodies targeting multidrug-resistant organisms and novel molecular and cellular therapeutic programs for oncology. For more information about Omeros and its programs, visit www.omeros.com. View source version on businesswire.com: https://www.businesswire.com/news/home/20260511546658/en/ Jennifer Cook Williams Cook Williams Communications, Inc. Investor and Media Relations IR@omeros.com Source: Omeros Corporation ### Related Stocks - [OMER.US](https://longbridge.com/en/quote/OMER.US.md) - [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md) - [PBE.US](https://longbridge.com/en/quote/PBE.US.md) - [LABU.US](https://longbridge.com/en/quote/LABU.US.md) - [BBH.US](https://longbridge.com/en/quote/BBH.US.md) - [XBI.US](https://longbridge.com/en/quote/XBI.US.md) - [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md) - [IBB.US](https://longbridge.com/en/quote/IBB.US.md) - [FBT.US](https://longbridge.com/en/quote/FBT.US.md) - [NVO.US](https://longbridge.com/en/quote/NVO.US.md) ## Related News & Research - [Omeros Q1 net income turns positive after YARTEMLEA launch](https://longbridge.com/en/news/286310334.md) - [Full Transcript: Cellectar Biosciences Q1 2026 Earnings Call](https://longbridge.com/en/news/286422585.md) - [Precigen Q1 revenue beats estimates on PAPZIMEOS launch](https://longbridge.com/en/news/286311056.md) - [Wave Life Sciences posts positive RestorAATion-2 data; WVE-006 restores M-AAT, cuts Z-AAT, supports monthly dosing](https://longbridge.com/en/news/286818220.md) - [Eton Pharmaceuticals Q1 product sales rise driven by portfolio expansion](https://longbridge.com/en/news/286461579.md)